Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

UPDATE 1-Canadian cannabis firm Aurora in talks to buy both CanniMed and Newstrike -sources

Published 2018-01-19, 05:33 p/m
Updated 2018-01-19, 05:40 p/m
© Reuters.  UPDATE 1-Canadian cannabis firm Aurora in talks to buy both CanniMed and Newstrike -sources

By John Tilak and Nichola Saminather

TORONTO, Jan 19 (Reuters) - Canadian marijuana producer Aurora Cannabis Inc ACB.TO is in talks with rivals CanniMed Therapeutics Inc CMED.TO and Newstrike Resources Ltd HIP.V to buy both businesses in a friendly deal that would create the nation's top weed company, people familiar with the matter told Reuters on Friday.

The deal signals an easing of tensions following an offer in November by Aurora, Canada's second-biggest listed cannabis producer, to buy CanniMed in an all-stock bid that was met with resistance from the target and a C$725 million ($580.4 million) lawsuit filed last week. combined company formed by a deal would inch ahead of industry leader Canopy Health's WEED.TO C$7.1 billion market value. The deal-making and fundraising frenzy comes as weed companies jostle for prime position ahead of the country's legalization of recreational use of marijuana in mid-2018.

Buying CanniMed and Newstrike would boost Aurora's capacity to meet the higher demand at home, as well as overseas as more countries approve the use of medical marijuana.

Aurora had strongly opposed a plan by CanniMed to purchase Newstrike. On Wednesday, Newstrike shareholders voted in favor of that deal, but on Thursday CanniMed postponed its investor vote on the acquisition to engage in talks with Aurora. the three companies fail to reach a deal, CanniMed could further postpone the vote, according to the people, who declined to be identified because they were not authorized to speak publicly about the matter.

While Aurora now prefers to acquire both companies, it could also settle for just CanniMed if talks with Newstrike fail, the sources said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Under Aurora's original bid, which was capped at C$24 a share, if CanniMed were to buy Newstrike, Aurora's offer would not proceed. sources said Aurora is ready to raise its offer price for CanniMed and would look to use its own stock, which has been on a tear alongside the rest of the Canadian cannabis industry.

CanniMed shares closed up 6.7 percent at C$34.77 in Toronto. Aurora stock was up 3.9 percent at C$13.48. Newstrike gained 5 percent to C$1.47.

"We said from the beginning that we'd be happy to sit down for friendly, collaborative discussions, so we're going in with an open mind," Aurora Chief Corporate Officer Cam Battley told Reuters on Friday. "Perhaps there's an opportunity to do something on a friendly basis."

A CanniMed representative declined to comment.

A Newstrike representative did not immediately respond to a request for comment.

With this latest development, both Aurora's offer for CanniMed and CanniMed's bid for Newstrike would be scrapped and replaced with a new friendly agreement, the people said.

The deal could be announced as early as Monday, the people said, while cautioning that there is no certainty an agreement would be reached.

Aurora had more than C$500 million of cash and marketable securities as of Dec. 31, it said on Jan. 2.

The talks between the three parties started earlier this week, the people said. ($1 = 1.2491 Canadian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.